Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Jansen

Anesthesiology Little Rock, AR Medical Doctor

NPI 1376556746 CMS profile 716049

1 Childrens Way # 203, Little Rock, AR 72202

Open in the dashboard

General payments

$1,082

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Jansen of Little Rock, AR is reported in the CMS Open Payments database as having received $1,082 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $169 3
2023 General $198 6
2022 General $221 7
2021 General $139 8
2020 General $209 8
2019 General $147 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Jansen
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Joseph Jansen were reported at $169. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Joseph Jansen Anesthesiology median Middle half National median
2019 $147 $72 $23–$151 $163
2020 $209 $36 $17–$120 $114
2021 $139 $49 $21–$135 $132
2022 $221 $52 $22–$144 $149
2023 $198 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $169 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $179 5 payments
  2. Abbott Laboratories $147 3 payments
  3. Vericel Corporation $124 1 payment
  4. Stimwave Technologies Incorporated $94 3 payments
  5. Medtronic USA, Inc. $75 2 payments
  6. Biodelivery Sciences International, Inc. $58 3 payments
  7. AbbVie, Inc. $44 2 payments
  8. Daiichi Sankyo Inc. $41 2 payments
  9. Zyla Life Sciences $37 3 payments
  10. Collegium Pharmaceutical, Inc. $34 2 payments
  11. Other $248 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,067 41 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. Infinion 16 $142 2 payments
  2. PROCLAIM $127 1 payment
  3. Nexobrid $124 1 payment
  4. CFNS StimQ Peripheral Nerve StimulatorSystem $81 2 payments
  5. SCS FreedonSpinal Cord Stimulator $81 2 payments
  6. INTELLIS $75 2 payments
  7. BELBUCA $46 2 payments
  8. BOTOX $44 2 payments
  9. SPRIX $37 3 payments
  10. XTAMPZA $34 2 payments
  11. Other $435 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

200

Median for Anesthesiology: 322

Drug cost

$11,573

Median for Anesthesiology: $8,738

Branded share of claims

25.5%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $8,036
Venlafaxine Hcl Er Venlafaxine Hcl Brand 12 $723
Atorvastatin Calcium Generic 28 $645
Humulin R Insulin Regular, Human Brand 12 $616
Pravastatin Sodium Generic 12 $309
Pantoprazole Sodium Generic 30 $299
Potassium Chloride Generic 18 $273
Losartan Potassium Generic 13 $246
Amlodipine Besylate Generic 24 $165
Escitalopram Oxalate Generic 12 $136

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$9,899

Medicare's payments for the services billed

Medicare patients

83

Average age 74

Services billed

88

43 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 49%
Arthritis 49%
Diabetes 34%
Ischemic heart disease 31%
Chronic kidney disease 22%
Depression 22%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record